May 26, 2024

Bionpa

You are Your Only Limit

Should Biotechnology Stock Mereo BioPharma Group plc

2 min read
News Home

Monday, April 17, 2023 03:18 PM | InvestorsObserver Analysts

Mentioned in this article

The 83 rating InvestorsObserver gives to Mereo BioPharma Group plc – ADR (MREO) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 96 percent of stocks in the Biotechnology industry, MREO’s 83 overall rating means the stock scores better than 83 percent of all stocks.

Overall Score - 83
MREO has an Overall Score of 83. Find out what this means to you and get the rest of the rankings on MREO!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What’s Happening With Mereo BioPharma Group plc – ADR Stock Today?

Mereo BioPharma Group plc – ADR (MREO) stock is down -1.43% while the S&P 500 is higher by 0.15% as of 3:18 PM on Monday, Apr 17. MREO has fallen -$0.01 from the previous closing price of $1.05 on volume of 1,445,508 shares. Over the past year the S&P 500 is lower by -5.65% while MREO is higher by 15.73%. MREO lost -$0.02 per share the over the last 12 months.

Click Here to get the full Stock Report for Mereo BioPharma Group plc – ADR stock.

You May Also Like

bionpa.com All rights reserved. | Newsphere by AF themes.